Belimumab paediatric trial results 'consistent with adult studies'

Longer follow-up needed to see renal outcomes, commentator says

Intravenous belimumab 10mg/kg every four weeks was safe and effective in childhood-onset systemic lupus erythematosus (SLE) say the authors of a phase-2 placebo-controlled trial.

filling a syringe from a vial

US researchers randomised 93 children between the ages of 5-17 (median 14.5 years, 45% female) to 10mg/kg IV belimumab or placebo every four weeks, plus standard SLE therapy.

At week 52, there were more SLE Responder Index responders with belimumab versus placebo (53% vs 44%), although the results for this primary end point